

### Early subclinical left ventricular dysfunction post radiotherapy in breast cancer: speckle-tracking echocardiography detects dose-related longitudinal strain changes after irradiation (BACCARAT study)

Sophie Jacob, Valentin Walker, Olivier Fondard, Atul Pathak, Baptiste Pinel, Gaëlle Jimenez, Jeremy Camilleri, David Broggio, Sylvie Derreumaux, Marie Odile Bernier, et al.

#### ▶ To cite this version:

Sophie Jacob, Valentin Walker, Olivier Fondard, Atul Pathak, Baptiste Pinel, et al.. Early subclinical left ventricular dysfunction post radiotherapy in breast cancer: speckle-tracking echocardiography detects dose-related longitudinal strain changes after irradiation (BACCARAT study). 30es Journées Européennes de la Société Française de Cardiologie / 30th European Days of the French Society of Cardiology, JESFC, Jan 2020, PARIS, France. hal-03098810

#### HAL Id: hal-03098810 https://hal.science/hal-03098810

Submitted on 5 Jan 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



### Early subclinical left ventricular dysfunction post radiotherapy in breast cancer: Speckle-tracking echocardiography detects dose-related longitudinal strain changes after irradiation (BACCARAT study)

Sophie Jacob, Valentin Walker, Olivier Fondard, Atul Pathak, Baptiste Pinel, Christian Chevelle, Gaëlle Jimenez, Jérémy Camilleri, David Broggio, Sylvie Derreumeaux, Marie-Odile Bernier, Dominique Laurier, Jean Ferrières, Olivier Lairez









I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company or I receive compensation or fees or research grants with a commercial company :


#### Speaker's name : Sophie Jacob, Fontenay Aux Roses Cedex

I do not have any potential conflict of interest




### **Breast cancer RT:** exposure of the heart to ionizing radiation

- Mean heart doses: 2-4 Gy for left sided breast cancer
- Heterogeneity of doses





Association between breast RT and long term cardiac complications






Subclinical left ventricular dysfunction can be detected early after BC RT with longitudinal strain (LS) measurement based on 2D speckle tracking







But no measurable alteration of LVEF

- Higher sensitivity and prognostic value of the global longitudinal strain (GLS), compared with left ventricular ejection fraction (LVEF), for early detection of left ventricular dysfunction
  - Patients with a relative drop in GLS> 10% 15% : this threshold is considered to define subclinical left ventricular dysfunction and has been reported to be predictive of subsequent cardiotoxicity (Thavendiranathan P et al. J Am Coll Cardiol. 2014;63:2751–68)
  - Chemotherapy-induced cardiotoxicity : drop > 10% of LVEF to a value < 53%</p>



Based on a prospective cohort of BC patients treated with 3D-CRT

To analyze the associations between radiation exposure to the whole heart and the left ventricle (LV) and the evolution of GLS from baseline to 6 months after RT, in particular for subclinical left ventricular dysfunction defined as GLS decrease > 10%.


## 30 Material and Methods


- Prospective cohort study
- BC patients of the BACCARAT study
  - RT between October 2015 and December 2017 in Clinique Pasteur Toulouse
  - Aged 40-75 years
  - No chemotherapy
  - > No history of major cardiac disease
  - ➢ LVEF > 45%
  - Echocardiography 2D speckle tracking (Siemens) performed before **RT and 6 months after RT**
- Solution Strain (GLS) at baseline and RT+6months
- Cardiac dosimetry (doses in Gy)


### 30 Baseline characteristics

	All patients N = 79
Age in years, mean ± SD	58 ± 9
Left-sided BC patients	64 (81%)
Hormonotherapy	60 (76%)
Anti-aromatase	34
Tamoxifen	26
Body mass index in kg/m², mean ± SD	24.4 ± 4.1
Smoking, n (%)	
Never-smokers	42 (53%)
Former smokers	23 (29%)
Current smokers	14 (18%)
Hypertension, n (%)	19 (24%)
Diabetes, n (%)	5 (6%)
Hypercholesterolemia, n (%)	24 (30%)

	Left-sided B( N = 6		Right-sided BC N = 15	
	Mean ± SD Median (Q1-Q3)	Range	Mean ± SD Median (Q1-Q3)	Range
eart Dmean (Gy) V20 (%)	<mark>3.05</mark> ± 1.31 3 (1 − 6)	0.87 – 6.37 0 - 10	<mark>0.65</mark> ± 0.49 0	0.25 – 2.17 0
eft Ventricle Dmean (Gy) V20 (%)	<mark>6.68</mark> ± 3.36 11 (4 – 18)	1.16 – 13.42 0 - 26	0.09 (0.08 – 0.12) 0	0.06 – 1.24 0








# Se Echographic measurements

	All BC patients N = 79	Left-sided BC patients N = 64	Right-sided BC patients N = 15	70    60    50    40
LVEF (in %) Before RT RT+6months	60 ± 9	61 ± 7 60 ± 9	64 ± 8 63 ± 8	30
p-value GLS (in %) Before RT RT+6months p-value	-16.1 ± 2.7 -15.1 ± 3.2	0.09 -16.0 ± 2.6 -15.0 ± 3.0 <b>0.02</b>	0.51 -16.2 ± 2.8 -15.2 ± 4.0 0.26	0 <b>LVEF GLS</b>
Patients with GLS reduction >10% after RT	37 (47%)	31 (48%)	6 (40%)	-30 V0 V6

## GLS reduction & cardiac dose



## 30 Non radiation factors

### **Event:** GLS reduction 6 months post RT > 10%

	OR (95% CI)	p-value
Age (in years)	0.98 (0.93 – 1.04)	0.52
BMI (in Kg.m-²)	1.15 (1.02 – 1.30)	0.02 <sup>a</sup>
Smoking		
Former vs. No	0.59 (0.20 - 1.68)	0.31
Current vs No	1.98 (0.57 – 6.91)	0.28
Hypertension	1.03 (0.37 – 2.89)	0.95
Diabetes	1.76 (0.28 – 11.19)	0.55
Hypercholesterolemia	1.95 (0.74 – 5.15)	0.18ª
Endocrine therapy	3.20 (1.02 - 10.10)	<b>0.04</b> <sup>a</sup>
Anti-aromatase	4.52 (1.32 – 15.53)	0.02
Tamoxifen	2.05 (0.57 - 7.41)	0.27

# 30 Association between doses and JESFC GLS reduction >10%

Associations between cardiac radiation doses and subclinical LV dysfunction (GLS reduction >10%) after RT.

	Univariate ana	lysis
	OR (95% CI)	p-value
Laterality of BC (left vs. right)	1.41 (0.45 – 4.42)	0.55
Heart Dmean (Gy)	1.37 (1.01 – 1.86)	0.04
V20 (%)	1.20 (1.01 – 1.43)	0.04
Left Ventricle Dmean (Gy)	1.14 (1.01 – 1.28)	0.03
V20 (%)	1.08 (1.01 – 1.14)	0.02
	Gy in mean LV do sed risk of GLS	



- Subclinical LV dysfunction defined as a GLS decrease>10% is associated with cardiac doses: dose-response relationship
- Non-radiation factors such as hormonal treatment : mandatory to evaluate the impact of radiation independently of other risk factors
- Dosimetry of the LV (V20) : may be promising to identify high risk subpopulations

Walker et al. Radiation Oncology 2019, 14 (1), 204.

### Perspectives:

- Multilayer and territorial analysis according to coronary arteries
- Evolution of GLS 24 months after RT



### THANK YOU FOR YOUR ATTENTION